07-07-2008, 10:37 AM
|
#11 |
| V.I.P. Member
Join Date: Jul 2006 Age: 27 Posts: 1,650
|
High doses of glucosamine result in insulin resistance: Quote:
Diabetologia. 2005 Oct;48(10):2131-9. Epub 2005 Jul 30. Related Articles, Links
Acute glucosamine-induced insulin resistance in muscle in vivo is associated with impaired capillary recruitment.
Wallis MG, Smith ME, Kolka CM, Zhang L, Richards SM, Rattigan S, Clark MG.
Biochemistry, School of Medicine, University of Tasmania, Private Bag 58, Hobart, Tasmania 7001, Australia.
AIMS/HYPOTHESIS: Glucose toxicity and glucosamine-induced insulin resistance have been attributed to products of glucosamine metabolism. In addition, endothelial cell nitric oxide synthase is inhibited by glucosamine. Since insulin has endothelial nitric-oxide-dependent vasodilatory effects in muscle, we hypothesise that glucosamine-induced insulin resistance in muscle in vivo is associated with impaired vascular responses including capillary recruitment. MATERIALS AND METHODS: Glucosamine (6.48 mg kg(-1) min(-1) for 3 h) was infused with or without insulin (10 mU kg(-1) min(-1)) into anaesthetised rats under euglycaemic conditions. RESULTS: Glucosamine infusion alone increased blood glucosamine (1.9+/-0.1 mmol/l) and glucose (5.4+/-0.2 to 7.7+/-0.3 mmol/l) (p<0.05) but not insulin. Glucosamine induced both hepatic and muscle insulin resistance as evident from measures of glucose appearance and disposal as well as hind-leg glucose uptake, which was inhibited by approx. 50% (p<0.05). Insulin-mediated increases in femoral arterial blood flow and capillary recruitment were completely blocked by glucosamine. CONCLUSION/INTERPRETATION: Glucosamine mediates a major impairment of insulin action in muscle vasculature associated with the insulin resistance of muscle. Further studies will be required to assess whether the impaired capillary recruitment contributes to insulin resistance.
PMID: 16059714
Am J Med Sci. 2007 Jun;333(6):333-9.Click here to read Links
Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance.
Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH.
Endocrinology Division, Department of Medicine, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA.
BACKGROUND: Glucosamine is used to treat osteoarthritis. In animals, the compound is known to cause insulin resistance, the underlying abnormality in type 2 diabetes mellitus. Insulin resistance in humans taking oral glucosamine in doses used for osteoarthritis has not been studied. METHODS: Volunteer human subjects (n = 38) without known abnormality of glucose homeostasis had fasting serum glucose, insulin, and lipids determined before and after taking 1500 mg glucosamine by mouth every day for 6 weeks. Fasting insulin and glucose were used to calculate homeostasis model assessment (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI). Vascular elasticity was measured by pulse wave analysis. The paired Student's t test was used to compare baseline with posttreatment values. Pearson's correlation was used to determine the relation of baseline HOMA-IR with changes in other variables. RESULTS: We found a rise in HOMA-IR after 6 weeks of glucosamine (2.8 versus 3.2, P < 0.04). The fall in HOMA-IR among the subjects was statistically related to a higher baseline HOMA-IR by Pearson's correlation(P < 0.01). A rise in serum triglycerides and a rise in LDL cholesterol were statistically related to baseline HOMA-IR. Small artery elasticity fell, and the decrease was higher in those with the highest baseline HOMA-IR. CONCLUSIONS: Notwithstanding its efficacy remaining in question, glucosamine is widely used as treatment for osteoarthritis, which is a condition associated with both obesity and type 2 diabetes mellitus. Our data indicate that persons with underlying poorer insulin sensitivity are at risk for worsening insulin resistance and vascular function with the use of glucosamine in doses used to treat osteoarthritis.
PMID: 17570985
| Br
__________________ Nimirum insanus paucis videatur, eo quod Maxima pars hominum morbo jactatur eodem.
ZiR RED has not been evaluated by the FDA.
ZiR RED is not intended to diagnose, treat, cure or prevent any disease. This is a warning: I am not a Medical Doctor.
This means you can not turn your brain off when taking advice from me, and can not sue me. www.BrPhysicalPerformance.com www.bodybuilding.com/fun/bigred.htm
NSCA: CSCS, CPT |
|
|
|
